Sector Intelligence · Life Sciences · June 2026
Life Sciences Investment 2026
UK and global life sciences investment data, deal activity and market intelligence — for investors, family offices and private wealth owners.
Market Data
The Numbers Shaping Life Sciences in 2026
£3.37bn
UK life sciences venture capital investment in 2025 — a -12% change on the prior year but still outperforming long-term historical averages.
Source: CBRE UK Life Sciences Outlook 2026
$15.2bn
Investment in cell and gene therapies in 2025 — a 30% increase over 2023 — reflecting heavy focus on customised therapies.
Source: BioPharma APAC January 2026
£520m
UK Government Life Sciences Innovative Manufacturing Fund, reaffirmed in the July 2025 Life Sciences Sector Plan as a headline government action.
Source: Cushman & Wakefield UK Life Sciences Marketbeat Q1 2026
63%
Rise in global licensing and partnership upfront and milestone payments as pharma and biotech leaned more heavily on collaborations to advance pipelines.
Source: Cushman & Wakefield Life Sciences Update February 2026
Investment Landscape
The Life Sciences Market in 2026
The UK life sciences sector enters 2026 from a position of resilience. Scientific output continued to grow and the UK's universities and research hospitals maintained their global influence. As the market moves into 2026, it is broadening beyond traditional wet-lab life sciences into a wider innovation economy — with AI-driven drug discovery, quantum technologies, advanced materials and synthetic biology increasingly shaping demand.
Major 2026 investment commitments into UK life sciences include AstraZeneca's £300 million investment reversal, Bristol Myers Squibb's £380 million commitment, UCB's £500 million investment and Boehringer Ingelheim's AI Accelerator launch in London.
AI-driven drug discovery is accelerating, attracting record investment and reshaping development timelines. The patent cliff is driving increased M&A and licensing as pharma works to rebuild pipelines and offset future revenue losses.
What Investors Are Targeting
Assets Attracting Capital in Life Sciences
AI Drug Discovery Platforms
Nearly half of industry executives rate digital transformation and AI as top strategic drivers. AI and ML platforms streamline drug discovery — target identification, design — optimise clinical trial design and enable real-time analytics. Venture capital flows heavily into AI-driven diagnostics and remote health tools.
Cell and Gene Therapy
Investment in CGTs reached $15.2 billion in 2025 — a 30% jump over 2023. With advances in genomics and biomarkers, treatments are increasingly tailored to individual patients.
Life Sciences Real Estate
Approximately 3.3 million square feet of life sciences space is under construction and 6.5 million square feet has planning approval, concentrated in the Golden Triangle of London, Oxford and Cambridge. R&D investment sales totalled $9.8 billion in 2025, up 29% year-on-year.
Key Risks
Risks for Life Sciences Investors in 2026
- Biotech funding volatility — capital markets remain selective on early-stage drug development
- Patent cliff creating pipeline pressure for large-cap pharma acquirers
- Life sciences real estate vacancy at 23.1% globally — supply/demand rebalancing ongoing
- US FDA policy uncertainty affecting development strategies and CRO demand
Subscribe
Stay Informed on Healthcare Investment
Subscribe to Healthcare Investor Magazine — independent investment intelligence for investors, family offices and private wealth owners.
FAQs
Frequently Asked Questions
Related Sectors
Explore Other Investment Sectors
Published for informational purposes only. Does not constitute financial or investment advice. All data sourced from primary institutional sources as cited. Seek independent professional advice before making any investment decision.